MRKR

Over the past six months, Marker Therapeutics' stock has been influenced by several events. Encouraging Phase 1 APOLLO data for MT-601 in relapsed B cell lymphomas was reported. The company reported its year-end 2025 corporate and financial results, with revenue of $3.55 million and losses of -$12.16 million. Marker Therapeutics presented at healthcare conferences and announced the first patient treated in its Off-the-Shelf program. A Baylor College of Medicine pancreatic cancer study featuring Marker Therapeutics' MAR-T Cell Technology was highlighted. The stock price has decreased by 2.0% since the start of the year, but has increased by 67.82% over the past six months.